Who to call at Recursion Pharmaceuticals, Inc., and when
Fundz watches for the moments Recursion Pharmaceuticals, Inc. starts buying, and tells you who to reach.
- An alert the day Recursion Pharmaceuticals, Inc. raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Recursion Pharmaceuticals, Inc., from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Recursion Pharmaceuticals, Inc.. With Fundz connected, it knows.
Recursion Pharmaceuticals, Inc.
A senior executive or director joined, left, or changed roles. An 8-K is the notice a US public company must file within four business days of a major event.
recursion.comAI Executive Summary
AI-powered analysis of 8-K filing content
Recursion Pharmaceuticals named Najat Khan, Ph.D., its current Chief Research and Development Officer and Chief Commercial Officer, as CEO and President, and appointed outgoing CEO Christopher Gibson, Ph.D., as Board Chair, both effective January 1, 2026. The change moves a current senior R&D and commercial leader into the top role, which may shape the company's strategic direction.
Key Takeaways
Najat Khan, Ph.D., who has served as Chief Research and Development Officer and Chief Commercial Officer since July 2024 and as a Board member since April 2024, becomes CEO and President effective Jan
Christopher Gibson, Ph.D., steps down as CEO and President effective January 1, 2026, and becomes Chair of the Board, so the company keeps its founder-level continuity at the board level.
3 more takeaways
Filing Overview
What This Means
Recursion Pharmaceuticals, Inc. filed with the SEC. Fundz turns 8-K material events into an alert with the right executive attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
4 screens from a live account. No signup.